Among the newly diagnosed prostate cancer patients who applied to our clinic between October 2020 and October 2021, a comprehensive assessment categorized 499 non-metastatic patients who underwent staging by 68Ga PSMA PET-CT as Group 1, while 243 patients with de novo metastatic conditions were designated as Group 2. Here, FOLH1 is linked to prostate cancer.